Compare FEED & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FEED | HSCS |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | 14 | 12 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 6.4M |
| IPO Year | N/A | N/A |
| Metric | FEED | HSCS |
|---|---|---|
| Price | $0.66 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 595.7K | 34.4K |
| Earning Date | 04-15-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $1.63 |
| 52 Week High | $6.09 | $6.47 |
| Indicator | FEED | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 27.04 | 45.25 |
| Support Level | N/A | $1.77 |
| Resistance Level | $0.97 | $2.18 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 5.94 | 25.93 |
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.